India's largest drugmaker, Sun Pharma, is considering a major acquisition. The company is evaluating the purchase of US-based ...

Arch Biopartners Inc. ('Arch” or the 'Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today the appointment of Dr.

A surge in deals and financings had the industry abuzz heading into this year’s J.P. Morgan Healthcare Conference. But some ...

Larimar Therapeutics is deeply undervalued, trading at ~$3.40 despite a de-risked safety profile and a clear regulatory path ...

Mergers and licensing deals are accelerating as the global market valuation nears quarter-trillion mark. The global market ...

Drugmaker CEOs see sales online channels as a budding opportunity, while some biotech investors told BioPharma Dive to expect ...

The firm said at the JP Morgan Healthcare Conference that it wants zorevunersen to be approved as a disease-modifying ...

Three years after the accelerated approval of its anti-amyloid Alzheimer’s therapy, Biogen—neck and neck in the market with ...

Biogen Inc.’s new at-home Alzheimer’s drug will give the company an edge over rival Eli Lilly Co.’s competing therapy, its ...

Investing.com -- Biogen Inc. ’s new at-home Alzheimer’s drug will provide an advantage over Eli Lilly Co. ’s competing ...

Venture investors are adopting a more aggressive mindset heading into 2026, while Merck, Moderna and Summit are all approaching crucial trial readouts.

During the first day of the 44 th Annual JP Morgan Healthcare Conference in San Francisco, a clear narrative emerged. With ...